Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, will be moving exchanges. The company has announced that it received conditional listing approval from the NYSE American LLC stock exchange. The NYSE American is designed for growing companies and offers investors a variety of ways in which to trade. The exchange is a competitively priced venue that blends unique features derived from the NYSE, such as electronic Designated Market Makers (“e-DMMs”) with quoting obligations for each NYSE American-listed company, with NYSE Arca’s fully electronic price/time priority execution model. The company noted in making the announcement that any listing is subject to the approval of the NYSE American and that all applicable regulatory requirements must be met. Cybin anticipates maintaining its listing on the NEO Exchange even after moving to the NYSE American exchange, where it will trade using the ticker CYBN. “Conditional listing approval on the NYSE American is an important milestone in Cybin’s growth journey,” said Cybin CEO Doug Drysdale. “We expect expanded access to investors to further fuel our mission to develop revolutionary psychedelic therapeutics for patients suffering from mental health conditions.”
To view the full press release, visit https://ibn.fm/GysgY
About Cybin Inc.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.